RecruitingPhase 1NCT07304128

A Study of PLB-002 in Advanced Solid Tumors

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of PLB-002 (Anti-Claudin 6 ADC) in Adults With Advanced Solid Tumors

Sponsor

Primelink BioTherapeitics(ShenZhen) Limited

Enrollment

100 participants

Start Date

Feb 6, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor

Summary

This study will test the safety, including side effects, and determine the characteristics of a drug called PLB-002 in participants with solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called PLB-002 in people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy, non-small cell lung cancer (NSCLC), and other specific tumor types. This is an early-phase study primarily looking at safety, tolerability, and the right dose. **You may be eligible if...** - You are 18 or older - You have a confirmed advanced solid tumor — including platinum-resistant ovarian cancer, NSCLC, or other tumor types specified in the protocol - Your cancer has progressed despite standard treatments - You are in good enough overall health - Your organ function (kidney, liver, bone marrow) meets minimum requirements **You may NOT be eligible if...** - You do not have one of the eligible tumor types - You have untreated brain metastases - You have serious heart, kidney, or liver problems - You are pregnant or breastfeeding - You have recently received certain other cancer therapies Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.